The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF. (Q54786239)

3 June 2018

title

The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF. (English)

1 reference

3 June 2018

author name string

Takeshi Yoshida

1

1 reference

3 June 2018

Isamu Okamoto

2

1 reference

3 June 2018

Tsutomu Iwasa

3

1 reference

3 June 2018

Masahiro Fukuoka

4

1 reference

3 June 2018

Kazuhiko Nakagawa

5

1 reference

3 June 2018

language of work or name

English

0 references

publication date

21 November 2008

1 reference

3 June 2018

published in

FEBS Letters

1 reference

3 June 2018

volume

582

1 reference

3 June 2018

issue

30

1 reference

3 June 2018

page(s)

4125-4130

1 reference

3 June 2018

Cisplatin: mode of cytotoxic action and molecular basis of resistance

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Ultraviolet irradiation induces keratinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Wound-induced HB-EGF ectodomain shedding and EGFR activation in corneal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Reactive oxygen species generation is involved in epidermal growth factor receptor transactivation through the transient oxidization of Src homology 2-containing tyrosine phosphatase in endothelin-1 signaling pathway in rat cardiac fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Cisplatin-induced activation of the EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Receptors for epidermal growth factor and other polypeptide mitogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Cellular survival: a play in three Akts

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Regulation of MAPKs by growth factors and receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2008.11.010

10.1016/J.FEBSLET.2008.11.010

21 January 2018

Identifiers

DOI

1 reference

3 June 2018

release_rqshmcyjpfhb5lv54qiu7h7iy4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rqshmcyjpfhb5lv54qiu7h7iy4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

3 June 2018